Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...